The recent assessment of the phase II COAST clinical trial, which investigated the combination of the CD73 inhibitor oleclumab and durvalumab (anti-PD L1) for treating locally advanced NSCLC, has demonstrated potential in prolonging the overall survival of patients after radiotherapy and chemotherapy [81].This outcome is strongly linked to the activation of the STING pathway. This evidence concerns the gene NT5E and non-small cell lung carcinoma.